A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
Gilead Sciences
Newave Pharmaceutical Inc
MacroGenics
Acerta Pharma BV
Xencor, Inc.
Astellas Pharma Inc
Mustang Bio
Morphotek
INSYS Therapeutics Inc